I recently came across Dr David Hunter’s LinkedIn post about about his Washington Post piece on the FDA’s October 2025 decision to reject SYD-101, a low-dose atropine treatment for progressive childhood myopia. The article focused on the confusing regulatory reasoning — behind the decision not to license SYD-101 in the US. On face value, it is confusing!
